CD8A and HIV-1 infection: This could be due to the different mechanisms for providing protection against HIV-1 infection between the Step and the RV144 vaccine regimens, as well as the lower sensitivity of the ICS assay to detect bulk T-cell responses compared to the ELISpot assay and the much lower CD8+ T-cell responses induced by the RV144 vaccine regimen.